Evidence map›Paper›PMID 33422027›Full record

ArticleBMC cancer2021

Comparison of long-term outcomes between Lynch sydrome and sporadic colorectal cancer: a propensity score matching analysis.

Yun Xu, Cong Li, Charlie Zhi-Lin Zheng, Yu-Qin Zhang, Tian-An Guo, Fang-Qi Liu, Ye Xu

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Yun XuDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, No. 270 Dong-An Road, Shanghai, 200032, China.
Cong LiDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, No. 270 Dong-An Road, Shanghai, 200032, China.
Charlie Zhi-Lin ZhengMechanical and Aerospace Engineering, University of California, 7400 Boelter Hall, Los Angeles, CA, 90095, USA.
Yu-Qin ZhangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Tian-An GuoDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Fang-Qi LiuDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, No. 270 Dong-An Road, Shanghai, 200032, China. liufq021@163.com.
Ye XuDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, No. 270 Dong-An Road, Shanghai, 200032, China. yexu@shmu.edu.cn.
Shanghai Medical College of Fudan University · CNFudan University Shanghai Cancer Center · CNUniversity of California, Los Angeles · US

Funding

National Natural Science Foundation of China 8147262
6 · The paper itself

Abstract

backgroundLynch syndrome (LS) is the most common hereditary colorectal cancer (CRC) syndrome. Comparison of prognosis between LS and sporadic CRC (SCRC) were rare, with conflicting results. This study aimed to compare the long-term outcomes between patients with LS and SCRC.

methodsBetween June 2008 and September 2018, a total of 47 patients were diagnosed with LS by genetic testing at Fudan University Shanghai Cancer Center. A 1:2 propensity score matching was performed to obtain homogeneous cohorts from SCRC group. Thereafter, 94 SCRC patients were enrolled as control group. All of enrolled patients received curative surgeries and standardized postoperative monitoring. The long-term survival rates between the two groups were compared, and the prognostic factors were also analyzed.

resultsThe 5-year overall survival rate of LS group was 97.6%, which was significantly higher than of 82.6% for SCRC group (χ

conclusionLS patients have better long-term survival prognosis than SCRC patients, even though the two groups have statistically comparable recurrence free survival. Combined chemotherapy is an effective treatment for LS patients who developed primary CRC recurrence. Standardized postoperative monitoring for LS patients may enable detection of metachronous tumors at earlier stages, which was a guarantee of a favorable prognosis despite lower tumor free survival.

Indexed as

Propensity ScoreAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCase-Control StudiesColorectal NeoplasmsColorectal Neoplasms, Hereditary NonpolyposisFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisRetrospective StudiesSurvival RateBiomarkers, TumorChemotherapyColorectal cancerLynch syndromeMismatch repairSurvival

Identifiers

PMID33422027
PMCPMC7797148
OpenAlexW3114627424

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.